Skip to main content
National Patient Survey 2024 logo.Our National Patient Survey 2024 report is now live. Thank you to all those that shared their experiences. Read our report here.

PGT-M conditions

The page below lists all PGT-M conditions currently authorised and awaiting consideration by the HFEA.

When publishing genetic conditions on the authorised list, we aim to be as consistent as possible with the OMIM database. However, many conditions may have several different names and we would recommend searching the list using the OMIM number for the condition as this is less likely to change throughout time.

If a condition does not appear on the list, it does not necessarily mean the condition has specifically not been authorised, it may mean that we have never before received an application from a UK centre to perform PGT-M for this condition and it has therefore never been considered by the HFEA.

Please note that we are always processing new applications to add genetic conditions to the list from UK centres licensed to perform PGT-M. This may mean that some authorised conditions may not be displayed. If you are unsure if a condition has been authorised or not, or would like any further information please contact the PGTM team at pgtm@hfea.gov.uk.

Click here for a downloadable list: approved condition list. Please note that the website page below is updated more regularly and is therefore more accurate than the downloadable list.

Condition name Status OMIM number Documents
Megalencephaly-Polymicrogyria-Polydactyly-Hydrocephalus Syndrome 3 (MPPH3) approved 615938
Megaloblastic Anemia due to Dihydrofolate Reductase Deficiency (DHFR) approved 613839
MEGDEL syndrome (3-Methylglutaconic Aciduria with Deafness, Encephalopathy, and Leigh-Like Syndrome) approved 614739
MEHMO Syndrome (MEHMO) approved 300148
Melanoma Pancreatic Cancer Syndrome approved 606719
Melanoma, cutaneous malignant, susceptibility to, 10 (CMM10) approved 615848
Melanoma, cutaneous malignant, susceptibility to, 2 (CMM2) approved 155601
Melanoma, cutaneous malignant, susceptibility to, 3 (CMM3) approved 609048
Melanoma-Astrocytoma Syndrome approved 155755
Melnick Needles Syndrome (MNS) approved 309350
Menkes Disease (MNK) approved 309400
Metabolic Crises, Recurrent, with Rhabdomyolysis, Cardiac Arrhythmias, and Neurodegeneration (MECRCN) approved 616878
Metachromatic Leukodystrophy (MLD) approved 250100
Metaphyseal Dysplasia without Hypotrichosis (MDWH) approved 250460
Metatropic Dysplasia (MTD) approved 156530
Methylmalonic Acidemia (MMA) approved 251000
Methylmalonic Aciduria and Homocystinuria, cblC Type (MAHCC) approved 277400
Methylmalonic Aciduria, cblA Type (MACA) approved 251100
Methylmalonic Aciduria, cblB Type (MACB) approved 251110
Microcephalic Osteodysplastic Primordial Dwarfism Type 1, (MOPD1) approved 210710